Thrombotic diseases, in particular cardiovascular and cerebrovascular thrombotic diseases, have become the top cause of death in the population of China, and their incidence has increased, seriously endangering human health.

China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Jinan Babio Biotechnology Co., Ltd. recently received an official notification from the EU Notified Body for its self-tested novel coronavirus antigen detection product, and subsequently obtained the CE certification issued by PCBC.

Thermo Fisher Scientific’s new Gibco CTS Xenon Electroporation System aims to provide easier scale up for cell therapies, from clinical development to commercial manufacturing.

Israeli diagnostics firm Todos Medical on Friday reported a nearly 13 percent year-over-year increase in revenues for the fourth quarter on increased demand for its COVID-19 testing products and services, as well as nutritional supplements.

On March 30, China National Medical Device Co., Ltd. (CNMD for short) under Sinopharm Group and Suzhou Hybiome Biomedical Engineering Co. Ltd., subsidiary of BioMerieux in China held a signing ceremony of the strategic cooperation agreement.

HTG Molecular Diagnostics reported after the close of the market on Tuesday that its 2021 revenues edged up 5 percent to $8.9 million from $8.5 million a year ago.

A recent study published in Nature Genetics identified 10 new genetic regions associated with Brugada syndrome, a cardiac arrhythmia disorder associated with sudden death in young adults.

On the morning of March 23, the National Industrial Innovation Center of Precision Medicine was inaugurated in Chengdu Tianfu International Bio-town.

Cue Health on Tuesday afternoon announced a whopping year-over-year uptick in revenues for the fourth quarter, beating the consensus Wall Street estimate.

Liquid biopsy performed on serum samples taken from breast cancer patients can provide increasingly accurate information on cancer progression and enable earlier detection of cancer recurrence, a new study from the University of Eastern Finland and Kuopio University Hospital shows.

On March 30, Rendu Biotechnology was listed on SSE Star Market, stock code: 688193. The issue price is 72.65 per share, and a total of 136,100 shares were issued.